RecruitMe Clinical Trial

A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION
Study of Cibisatamab in Combination with Atezolizumab in Patients with Colorectal Cancer
Sponsor:F. Hoffmann-La Roche Ltd
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS1555
U.S. Government ID:NCT03866239
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to explore the effects, good or bad, of Cibisatamab, atezolizumab, obinutuzumab, and tocilizumab on patients with Colorectal cancer (CRC). In this study, you will first get treated with obinutuzumab (hereafter referred to as pretreatment with obinutuzumab). About 2 weeks later, you will then get treated with Cibisatamab and atezolizumab. If you have a bad reaction to Cibisatamab and atezolizumab, you may also get treated with tocilizumab. About 50 people will take part in this study.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have histologically confirmed adenocarcinoma originating from the colon or rectum?YesNo
Have you experienced disease progression during or within 3 months?YesNo
Submit
Cancel
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162